(Q41731971)

8 October 2017

1 reference

title

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia (English)

1 reference

8 October 2017

1 reference

R L Ellen

1

1 reference

PubMed ID

9526816

8 October 2017

R McPherson

series ordinal

2

1 reference

PubMed ID

9526816

8 October 2017

language of work or name

English

0 references

publication date

1 February 1998

1 reference

American Journal of Cardiology

8 October 2017

1 reference

8 October 2017

81

1 reference

8 October 2017

60B-65B

1 reference

8 October 2017

4A

1 reference

Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia

8 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Combination drug therapy for familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Role of Lp A-I and Lp A-I/A-II in cholesteryl ester transfer protein-mediated neutral lipid transfer. Studies in normal subjects and in hypertriglyceridemic patients before and after fenofibrate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Long-term safety and efficacy profile of simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Rhabdomyolysis and simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Lovastatin and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Lovastatin-induced acute rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

Cholesterol-lowering agent myopathy (CLAM)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900040-X

10.1016/S0002-9149(98)00040-X

7 January 2021

Identifiers

DOI

1 reference

8 October 2017

1 reference

PubMed ID

9526816